← Incyte overview

Incyte vs Takeda Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Incyte Corporation (INCY)

Q3 2026
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

July 2026
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

Latest
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

Q2 2026
▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

June 2026
▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

Takeda Pharmaceutical Co. Ltd. (4502.JP)

Q3 2026
▲4

Takeda's Q3: New Drug Launches and AI Partnerships Drive Growth

  • Qdenga approved in India Takeda's dengue vaccine Qdenga became India's first approved dengue vaccine, opening a large new market and boosting the company's global vaccine business.

    This is a new approval that expands Takeda's vaccine reach and revenue potential.

  • ORZEYFUL launched in US and Japan ORZEYFUL, a first-in-class narcolepsy therapy, launched in the US and Japan, offering a new treatment option and adding a new revenue stream for Takeda.

    This is a new product launch that directly contributes to Takeda's sales growth.

  • MIMRYLO approved for polycythemia vera MIMRYLO received FDA approval for polycythemia vera, expanding Takeda's oncology portfolio. However, it requires up to $1.15 billion in milestone payments to a partner.

    This is a new approval that adds a new drug to Takeda's lineup, though with a financial obligation.

  • AI-developed zasocitinib beats Sotyktu in Phase 3 Zasocitinib, developed using AI, outperformed Sotyktu in a Phase 3 trial for psoriasis, and its NDA was accepted under priority review, with an FDA decision expected in early 2027.

    This is a major clinical win that could lead to a new blockbuster drug, though approval is not yet certain.

August 2026
▲4

Takeda's pipeline wins and AI edge drive the story

  • AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.

    It shows a technology edge that can drive future revenue and investor optimism.

  • Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.

    A new approval expands Takeda's commercial portfolio and revenue potential.

  • FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.

    A major U.S. approval adds a new growth driver, offset by milestone payments.

  • FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.

    It advances a key pipeline drug toward market, a clear positive catalyst.

Latest
▲4

Takeda's pipeline wins and AI edge drive the story

  • AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.

    It shows a technology edge that can drive future revenue and investor optimism.

  • Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.

    A new approval expands Takeda's commercial portfolio and revenue potential.

  • FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.

    A major U.S. approval adds a new growth driver, offset by milestone payments.

  • FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.

    It advances a key pipeline drug toward market, a clear positive catalyst.

July 2026
▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

  • Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.

    New approval expands market access and revenue potential for a key vaccine.

  • FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.

    Major product approval with first-in-class status drives future earnings.

  • Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.

    Strategic expansion into emerging market plasma supply adds growth optionality.

  • AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.

    AI adoption may enhance R&D productivity and pipeline value.

▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

  • Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.

    New approval expands market access and revenue potential for a key vaccine.

  • FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.

    Major product approval with first-in-class status drives future earnings.

  • Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.

    Strategic expansion into emerging market plasma supply adds growth optionality.

  • AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.

    AI adoption may enhance R&D productivity and pipeline value.

Q2 2026
▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

  • New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.

    Leadership change and strategic direction are major forces behind the stock's outlook.

  • Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.

    Strong clinical data directly increases the probability of a high-value new product.

  • Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.

    AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.

  • FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.

    Regulatory progress on an existing drug provides a near-term revenue opportunity.

June 2026
▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

  • New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.

    Leadership change and strategic direction are major forces behind the stock's outlook.

  • Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.

    Strong clinical data directly increases the probability of a high-value new product.

  • Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.

    AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.

  • FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.

    Regulatory progress on an existing drug provides a near-term revenue opportunity.

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

  • New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.

    Leadership change and strategic direction are major forces behind the stock's outlook.

  • Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.

    Strong clinical data directly increases the probability of a high-value new product.

  • Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.

    AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.

  • FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.

    Regulatory progress on an existing drug provides a near-term revenue opportunity.

© 2026 MarketIVWhy